- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01306786
Five Days Quadruple and Clarithromycin Containing Triple Therapy as Treatment for Helicobacter Pylori Eradication
Five Days Quadruple and Clarithromycin Containing Triple Therapy as Empirical First and Second-Line Treatment for Helicobacter Pylori Eradication: a Randomized Crossover Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hong Kong SAR, Hong Kong
- The University of Hong Kong, Queen Mary Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with H. pylori infection
- did not receive H. pylori eradication therapy before
Exclusion Criteria:
- patients who have received previous H. pylori eradication therapy
- co-morbidity of liver cirrhosis
- co-morbidity of renal failure
- co-morbidity of alcoholism
- co-morbidity of malignancy
- received antibiotics, bismuth preparations, proton pump inhibitors or probiotic in the preceding three months
- patients with known allergy to the medications used
- patients with a history of previous gastrointestinal diseases or gastric surgery
- pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Quadruple therapy
First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d. Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d |
First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d. Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d |
Active Comparator: Triple Therapy
First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
|
First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
H pylori eradication
Time Frame: 8 weeks after treatment
|
Successful H pylori eradication documented by urea breath test after first and second line treatments.
Cross over if patients failed first line treatment
|
8 weeks after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: 10 weeks outpatient follow-up
|
Assessed adverse effects and compliance by standard questionnaire upon 10 weeks outpatient follow-up
|
10 weeks outpatient follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ivan F Hung, MD MRCP, The University of Hong Kong
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- HKU-HP1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Helicobacter Pylori Infection
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingHelicobacter Pylori Infection | Helicobacter Pylori EradicationBangladesh
-
Shandong UniversityRecruitingHelicobacter Pylori Infection | Patient Education | Helicobacter Pylori EradicationChina
-
Shandong UniversityCompletedHelicobacter Pylori Infection Helicobacter Pylori Eradication Patient EducationChina
-
Shanghai Jiao Tong University School of MedicineCompletedCure Rate of Helicobacter Pylori InfectionChina
-
Seoul National University Bundang HospitalRecruitingHelicobacter Pylori Infection | Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation | Helicobacter Pylori Associated Gastrointestinal Disease | Helicobacter Pylori Infection, Susceptibility toKorea, Republic of
-
The First Affiliated Hospital of Nanchang UniversityUnknownBacterial Infection Due to Helicobacter Pylori (H. Pylori) | Eradication Therapy of Helicobacter Pylori | Detection of Helicobacter PyloriChina
-
Tanta UniversityNot yet recruitingPersistent Helicobacter Pylori InfectionEgypt
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedHelicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)Helicobacter Pylori Infection | Helicobacter Pylori gyrA Levofloxacin Resistance Mutation | Fecal Drug Resistance Gene Detection | Helicobacter Pylori Infection, Susceptibility toChina
-
Kaohsiung Veterans General Hospital.Kaohsiung Medical University Chung-Ho Memorial HospitalCompletedHelicobacter Pylori InfectionTaiwan
-
National Taiwan University HospitalCompleted
Clinical Trials on Quadruple therapy
-
Livzon Pharmaceutical Group Inc.Fifth Affiliated Hospital, Sun Yat-Sen UniversityCompletedHelicobacter Pylori Eradication Antibiotic
-
Les Laboratoires des Médicaments StérilesCompleted
-
National Taiwan University HospitalUnknownTriple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori InfectionHelicobacter Pylori InfectionTaiwan
-
University of AlbertaCanadian Institutes of Health Research (CIHR); Alberta Innovates Health Solutions and other collaboratorsCompleted
-
Chuncheon Sacred Heart HospitalHallym University Medical CenterCompletedHelicobacter Pylori InfectionKorea, Republic of
-
Xijing Hospital of Digestive DiseasesCompletedGastric Cancer | Helicobacter Pylori Infection | BismuthChina
-
National Cancer Center, KoreaCompletedHelicobacter Pylori Infection | Family History of Stomach CancerKorea, Republic of
-
The University of Texas Health Science Center,...Baylor College of Medicine; University of Texas; Texas Tech University; University...CompletedIron DeficiencyUnited States
-
National Cancer Center, KoreaPusan National University Hospital; Chonnam National University Hospital; Kyungpook... and other collaboratorsActive, not recruitingGastric Cancer | Helicobacter Pylori InfectionKorea, Republic of
-
The Third Xiangya Hospital of Central South UniversityCompletedHypertension | Arterial HypertensionChina